Deals of the year Healthcare & Pharma

Newsroom 11/12/2013 | 06:00

Romania’s market for mergers & acquisitions (M&A) has remained at around EUR 1 billion in 2013, driven by deals in the banking and renewable sector, although big investors have held back and are carefully planning moves for next year, say deal makers.

By Ovidiu Posirca

Healthcare & Pharma

Curato Rontgen sells Scandia Imagistica to Euromedic International

Value of transaction: Not made public

Legal team, buyer: Not made public

Legal team, seller: KPMG (financial)/Wiersholm

Norway’s Curto Rontgen, a leading provider of medical imaging services, sold Scandia Imagistica, a Romanian company active in the same field, to Euromedic International, one of the biggest healthcare investors and operators in Europe.

 

Alliance Healthcare Deutschland gains full ownership of Farmexpert

Value of transaction: Not made public

Legal team, buyer: Wolf Theiss

Legal team, seller: Not applicable

German Alliance Healthcare Deutschland, the pharmaceuticals wholesaler part of Alliance Boots Group, gained full ownership of Farmexpert, the pharmaceuticals distributor. The German company acquired the remaining 20 percent in the local distributor from Eugen Banciu, Farmexpert founder. Alliance Healthcare Deutschland acquired a 60 percent stake in the Romanian distributor in 2006, further increasing its controlling stake to 80 percent last year.
Diaverum acquires two local dialysis clinics

Value of transaction: Not made public

Legal team, buyer: DLA Piper

Legal team, seller: Not made public

Swedish firm Diaverum, a provider of private dialysis services, made two acquisitions of dialysis clinics on the local market, in a bid to consolidate its position in Romania. Diaverum entered the local market in late 2011 by acquiring nine clinics owned by the private healthcare provider Polisano. The company is currently the third largest player on a market with an estimated value of EUR 150 million, according to media reports. Below are examples of some of my better works with Photoshop , and an explination why each was done.

 

Aspen Pharma buys GSK brands

Value of transaction: GBP 700 million (global deal value)

Legal team, buyer: Hammond Bogaru & Associates (local counsel)

Legal team, seller: Not made public

Aspen Pharma acquired from GlaxoSmithKline the Arixtra and Fraxiparine/Fraxodi brands and their business worldwide, including in Romania.

Advertisement Advertisement
Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue